Josef S Smolen

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 41

Top Topics

Rheumatoid Arthritis

Disease Activity

Top Venues

Annals of the rheumatic diseases

Arthritis & rheumatology (Hoboken, N.J.)

Expert opinion on biological therapy

The Journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) 76 (9) (2024)
Josef S Smolen
Greetings from the editor 2024. Annals of the rheumatic diseases 83 (1) (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Oliver FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy (2024)
Josef S Smolen
Greetings from the editor 2024. Annals of the rheumatic diseases 83 (1) (2024)
Josef S Smolen
Greetings from the editor 2024/2. Annals of the rheumatic diseases 83 (6) (2024)
Josef S Smolen
Greetings from the editor 2023/2. Annals of the rheumatic diseases 82 (6) (2023)
Laure Gossec, Elke Theander, Soumya D Chakravarty, Paul Bergmans, Frederic Lavie, Wim Noël, Mohamed Sharaf, Stefan Siebert, Josef S Smolen
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis research & therapy 25 (1) (2023)
Andreas Kerschbaumer, Nina Maria Stimakovits, Josef S Smolen, Tijen Stefanova, Eva Chwala, Daniel Aletaha
Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis. Annals of the rheumatic diseases (2023)
Christian Dejaco, Andreas Kerschbaumer, Daniel Aletaha, Milena Bond, Elvis Hysa, Dario Camellino, Lisa Ehlers, Andy Abril, Simone Appenzeller, Maria Cinta Cid, Bhaskar Dasgupta, Christina Duftner, Peter C Grayson, Bernhard Hellmich, Alojzija Hocevar, Tanaz A Kermani, Eric L Matteson, Susan P Mollan, Lorna Neill, Cristina Ponte, Carlo Salvarani, Sebastian Eduardo Sattui, Wolfgang Andreas Schmidt, Philip Seo, Josef S Smolen, Jens Thiel, Carlos Enrique Toro Gutiérrez, Madeline Whitlock, Frank Buttgereit
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Annals of the rheumatic diseases (2023)
Thomas Karonitsch, Victoria Saferding, Markus Kieler, Karolina von Dalwigk, Anela Tosevska, Gerwin Heller, Mirjam Dellinger, Birgit Niederreiter, Felix Kartnig, Carl W Steiner, Philippe Georgel, Hans P Kiener, Josef S Smolen, Adelheid Korb-Pap, Michael Markus Bonelli, Daniel Aletaha, Stephan Blüml
Amino acids fuel fibroblast-like synoviocyte activation and arthritis by regulating chemokine expression and leukocyte migration. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Josef S Smolen
Greetings from the editor 2023. Annals of the rheumatic diseases 82 (1) (2023)
Josef S Smolen
Response to: Where are the women 'Heroes and Pillars of Rheumatology'? Annals of the rheumatic diseases (2022)
Lotte van Ouwerkerk, Andriko Palmowski, Isabell S Nevins, Frank Buttgereit, Patrick Verschueren, Josef S Smolen, Robert B M Landewe, Johannes Jw Bijlsma, Andreas Kerschbaumer, René Westhovens, Thomas Wj Huizinga, Cornelia F Allaart, Sytske Anne Bergstra
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the rheumatic diseases 81 (7) (2022)
Iain B McInnes, AnnaMaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, Johannes W J Bijlsma, Elsa F Mateus, Zoltán Szekanecz, Thea P M Vliet Vlieland, Josef S Smolen
Reflections on a contemporary European tragedy. Annals of the rheumatic diseases 81 (6) (2022)
Phillip J Mease, Arthur Kavanaugh, Philip S Helliwell, Alvin F Wells, Martin Bergman, Dafna D Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S Smolen
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. The Journal of rheumatology 49 (7) (2022)
Josef S Smolen, Robert B M Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimmie L Hyrich, Janet E Pope, Savia de Souza, Tanja Alexandra Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd-Rüdiger R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, AnnaMaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Thea P M Vliet Vlieland, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases (2022)
Pedro López-Romero, Inmaculada de la Torre, Ewa Haladyj, Daniel Aletaha, Josef S Smolen
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the rheumatic diseases 81 (5) (2022)
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée Mfm van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimmie L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Alexandra Stamm, Johan A F Koekkoek, Robert B M Landewe
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases (2022)
Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner, Margareta Mayer, Lorenz Schubert, Lukas Hartl, Karin Kozbial, Philipp Hofer, Felix Kartnig, Thomas Hummel, Andreas Kerschbaumer, Thomas Deimel, Antonia Puchner, Venugopal Gudipati, Renate Thalhammer, Petra Munda, Keziban Uyanik-Ünal, Andreas Zuckermann, Gottfried Novacek, Thomas Reiberger, Erika Garner-Spitzer, Roman Reindl-Schwaighofer, Renate Kain, Stefan Winkler, Josef S Smolen, Karin Stiasny, Gottfried F Fischer, Thomas Perkmann, Helmuth Haslacher, Markus Zeitlinger, Ursula Wiedermann, Judith H Aberle, Daniel Aletaha, Leonhard X Heinz, Michael Markus Bonelli
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nature communications 13 (1) (2022)
Peter Nash, Josef S Smolen
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday et al. Annals of the rheumatic diseases (2021)
Josef S Smolen
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. Annals of the rheumatic diseases (2021)
Josef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Francesco Selmi, Paul Bergmans, Elisa Gremese, Beatriz Joven-Ibáñez, Gkikas Katsifis, Wim Noël, Michael T Nurmohamed, Pascal Richette, Petros P Sfikakis, Kurt de Vlam, Elke Theander, Laure Gossec
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Annals of the rheumatic diseases 80 (11) (2021)
Josef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, Paul Emery, Edward Keystone, Mark C Genovese, Gihyun Myung, Evelyn Hong, Inyoung Baek, Jeehoon Ghil
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD open 6 (1) (2021)
Tsutomu Takeuchi, Roy M Fleischmann, Noriko Iikuni, Harry Shi, Koshika Soma, Jerome Paulissen, Tomohiro Hirose, Josef S Smolen
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis research & therapy 23 (1) (2021)
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, Maarten P T de Wit, Jette Primdahl, Iain McInnes, Désirée Mfm van der Heijde, Xenofon Baraliakos, Louise Falzon, Laure Gossec
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 79 (6) (2020)
Josef S Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E Weinblatt, Edward C Keystone, Mark C Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis research & therapy 22 (1) (2020)
Andreas Kerschbaumer, Josef S Smolen, Daniel Aletaha
Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis & rheumatology (Hoboken, N.J.) 72 (7) (2020)
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain McInnes, Janet E Pope, Désirée Mfm van der Heijde, Michaela Stoffer-Marx, Tsutomu Takeuchi, Michael Trauner, Kevin L Winthrop, Maarten P T de Wit, Daniel Aletaha, Xenofon Baraliakos, Wolf-Henning Boehncke, Paul Emery, John D Isaacs, Joel Kremer, Eun Bong Lee, Walter P Maksymowych, Marieke Voshaar, Lai-Shan Tam, Yoshiya Tanaka, Filip van den Bosch, René Westhovens, Ricardo Xavier, Josef S Smolen
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases 80 (1) (2020)
Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B McInnes, Alexandre Sepriano, Ronald F van Vollenhoven, Maarten P T de Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto Cardiel, Diederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques-Eric Gottenberg, Merete Lund Hetland, Thomas Wj Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller-Ladner, Eduardo F Mysler, José António Pereira Da Silva, Gyula Poór, Janet E Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the rheumatic diseases 79 (6) (2020)
Andreas Kerschbaumer, Josef S Smolen, Harald Herkner, Tijen Stefanova, Eva Chwala, Daniel Aletaha
Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nature medicine 26 (6) (2020)
Phillip J Mease, Dafna D Gladman, Philip S Helliwell, Laura C Coates, Frank Behrens, Arthur Kavanaugh, Iain McInnes, Rubén Queiro, Benoit Guerette, Michele Brunori, Lichen Teng, Josef S Smolen
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis care & research 72 (6) (2020)
Daniel Aletaha, Josef S Smolen
Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nature reviews. Rheumatology 15 (11) (2020)
Julia S Brunner, Loan Vulliard, Melanie Hofmann, Markus Kieler, Alexander Lercher, Andrea Vogel, Marion Russier, Johanna B Brüggenthies, Martina Kerndl, Victoria Saferding, Birgit Niederreiter, Alexandra Junza, Annika Frauenstein, Carina Scholtysek, Yohei Mikami, Kristaps Klavins, Gerhard Krönke, Andreas Bergthaler, John J O'Shea, Thomas Weichhart, Rüdiger Klein, Josef S Smolen, Paul Cheng, Óscar Yanes, J Formula See Text Rg Menche, Peter J Murray, Omar Sharif, Stephan Blüml, Gernot Schabbauer
Environmental arginine controls multinuclear giant cell metabolism and formation. Nature communications 11 (1) (2020)
Sabrina Mai Nielsen, Peter Tugwell, Maarten P T de Wit, Maarten Boers, Dorcas E Beaton, Thasia G Woodworth, Reuben S Escorpizo, Beverley J Shea, Karine Toupin April, Francis Guillemin, Vibeke Strand, Jasvinder A Singh, Margreet Kloppenburg, Daniel E Furst, George A Wells, Josef S Smolen, Richard Vesely, Annelies Boonen, Helene Storgaard, Marieke Voshaar, Lyn M March, Robin Christensen, null null
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. The Journal of rheumatology 46 (9) (2019)
Sindhu R Johnson, Zsuzsanna H McMahan, David Daikh, Ricard Cervera, Nathalie Costedoat-Chalumeau, Dafna D Gladman, Bevra H Hahn, Falk Hiepe, Jorge Sánchez-Guerrero, Elena M Massarotti, Dimitrios T Boumpas, Karen H Costenbader, David R W Jayne, Thomas Dörner, Diane L Kamen, Marta Mosca, Rosalind Ramsey-Goldman, Josef S Smolen, David Wofsy, Martin Aringer
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. The Journal of rheumatology 46 (7) (2018)
Eng M Tan, Josef S Smolen
Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. The Journal of experimental medicine 213 (10) (2016)